(CLBT) Cellebrite DI - Ratings and Ratios
Exchange: NASDAQ •
Country: Israel •
Currency: USD •
Type: Common Stock •
ISIN: IL0011794802
Forensics Software, Extraction Tools, Analysis Platform, Case Management
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 41.6% |
| Value at Risk 5%th | 58.9% |
| Relative Tail Risk | -13.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.19 |
| Alpha | -25.69 |
| CAGR/Max DD | 1.18 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.376 |
| Beta | 0.718 |
| Beta Downside | 0.590 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.00% |
| Mean DD | 12.46% |
| Median DD | 6.20% |
Description: CLBT Cellebrite DI November 08, 2025
Cellebrite DI Ltd. (NASDAQ: CLBT) supplies a comprehensive digital-forensics suite that enables legally sanctioned investigations across all continents. Its flagship products-Inseyets, Pathfinder, Smart Search, and Guardian-cover the full evidence lifecycle from acquisition and decoding to automated analysis, visualization, and case management, serving law-enforcement, border-control, and corporate security agencies tackling crimes such as child exploitation, terrorism, human trafficking, and cryptocurrency fraud.
In FY 2023 the company reported revenue of $215 million, up roughly 23 % year-over-year, with subscription-based recurring revenue now representing about 70 % of total sales and a gross margin near 78 %. Growth is being driven by expanding government budgets for cyber-crime response and the broader digital-forensics market, which is projected to compound at ~11 % annually through 2028. Cellebrite’s recent rollout of Endpoint Inspector and Endpoint Mobile Now extends its addressable enterprise base, adding a recurring-revenue stream beyond traditional law-enforcement contracts.
For a deeper quantitative assessment, you may find ValueRay’s analyst notes on CLBT useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (76.3m TTM) > 0 and > 6% of Revenue (6% = 27.4m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 77.10% (prev 59.33%; Δ 17.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 152.7m > Net Income 76.3m (YES >=105%, WARN >=100%) |
| Net Debt (-259.9m) to EBITDA (77.4m) ratio: -3.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (249.7m) change vs 12m ago 19.65% (target <= -2.0% for YES) |
| Gross Margin 83.96% (prev 84.45%; Δ -0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 62.30% (prev 61.21%; Δ 1.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 49.44 (EBITDA TTM 77.4m / Interest Expense TTM 1.35m) >= 6 (WARN >= 3) |
Altman Z'' 4.17
| (A) 0.42 = (Total Current Assets 668.4m - Total Current Liabilities 316.9m) / Total Assets 834.3m |
| (B) -0.13 = Retained Earnings (Balance) -107.8m / Total Assets 834.3m |
| (C) 0.09 = EBIT TTM 66.7m / Avg Total Assets 731.8m |
| (D) 1.16 = Book Value of Equity 447.8m / Total Liabilities 386.6m |
| Total Rating: 4.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.55
| 1. Piotroski 6.0pt |
| 2. FCF Yield 3.70% |
| 3. FCF Margin 30.51% |
| 4. Debt/Equity 0.05 |
| 5. Debt/Ebitda -3.36 |
| 6. ROIC - WACC (= 5.61)% |
| 7. RoE 19.63% |
| 8. Rev. Trend 97.63% |
| 9. EPS Trend 64.48% |
What is the price of CLBT shares?
As of December 02, 2025, the stock is trading at USD 17.14 with a total of 1,134,084 shares traded.
Over the past week, the price has changed by +1.54%, over one month by +3.13%, over three months by +4.77% and over the past year by -15.82%.
Over the past week, the price has changed by +1.54%, over one month by +3.13%, over three months by +4.77% and over the past year by -15.82%.
Is CLBT a buy, sell or hold?
Cellebrite DI has received a consensus analysts rating of 4.75.
Therefore, it is recommended to buy CLBT.
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CLBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.7 | 44.2% |
| Analysts Target Price | 24.7 | 44.2% |
| ValueRay Target Price | 21.2 | 23.8% |
CLBT Fundamental Data Overview November 22, 2025
Market Cap USD = 4.26b (4.26b USD * 1.0 USD.USD)
P/E Trailing = 45.8947
P/E Forward = 37.1747
P/S = 9.3519
P/B = 9.6437
Beta = 1.284
Revenue TTM = 455.9m USD
EBIT TTM = 66.7m USD
EBITDA TTM = 77.4m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.62m USD (from shortTermDebt, last quarter)
Debt = 21.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -259.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.76b USD (4.26b + Debt 21.4m - CCE 525.7m)
Interest Coverage Ratio = 49.44 (Ebit TTM 66.7m / Interest Expense TTM 1.35m)
FCF Yield = 3.70% (FCF TTM 139.1m / Enterprise Value 3.76b)
FCF Margin = 30.51% (FCF TTM 139.1m / Revenue TTM 455.9m)
Net Margin = 16.74% (Net Income TTM 76.3m / Revenue TTM 455.9m)
Gross Margin = 83.96% ((Revenue TTM 455.9m - Cost of Revenue TTM 73.1m) / Revenue TTM)
Gross Margin QoQ = 83.88% (prev 84.39%)
Tobins Q-Ratio = 4.51 (Enterprise Value 3.76b / Total Assets 834.3m)
Interest Expense / Debt = 6.29% (Interest Expense 1.35m / Debt 21.4m)
Taxrate = 16.88% (4.10m / 24.3m)
NOPAT = 55.4m (EBIT 66.7m * (1 - 16.88%))
Current Ratio = 2.11 (Total Current Assets 668.4m / Total Current Liabilities 316.9m)
Debt / Equity = 0.05 (Debt 21.4m / totalStockholderEquity, last quarter 447.7m)
Debt / EBITDA = -3.36 (Net Debt -259.9m / EBITDA 77.4m)
Debt / FCF = -1.87 (Net Debt -259.9m / FCF TTM 139.1m)
Total Stockholder Equity = 388.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.15% (Net Income 76.3m / Total Assets 834.3m)
RoE = 19.63% (Net Income TTM 76.3m / Total Stockholder Equity 388.9m)
RoCE = 16.25% (EBIT 66.7m / Capital Employed (Equity 388.9m + L.T.Debt 21.4m))
RoIC = 14.26% (NOPAT 55.4m / Invested Capital 388.9m)
WACC = 8.64% (E(4.26b)/V(4.28b) * Re(8.66%) + D(21.4m)/V(4.28b) * Rd(6.29%) * (1-Tc(0.17)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.33%
[DCF Debug] Terminal Value 79.46% ; FCFE base≈123.0m ; Y1≈151.7m ; Y5≈258.9m
Fair Price DCF = 16.01 (DCF Value 3.91b / Shares Outstanding 244.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.48 | EPS CAGR: 50.80% | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.63 | Revenue CAGR: 17.93% | SUE: 1.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=-0.005 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.025 | Revisions Net=+7 | Growth EPS=+7.4% | Growth Revenue=+16.9%
P/E Trailing = 45.8947
P/E Forward = 37.1747
P/S = 9.3519
P/B = 9.6437
Beta = 1.284
Revenue TTM = 455.9m USD
EBIT TTM = 66.7m USD
EBITDA TTM = 77.4m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.62m USD (from shortTermDebt, last quarter)
Debt = 21.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -259.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.76b USD (4.26b + Debt 21.4m - CCE 525.7m)
Interest Coverage Ratio = 49.44 (Ebit TTM 66.7m / Interest Expense TTM 1.35m)
FCF Yield = 3.70% (FCF TTM 139.1m / Enterprise Value 3.76b)
FCF Margin = 30.51% (FCF TTM 139.1m / Revenue TTM 455.9m)
Net Margin = 16.74% (Net Income TTM 76.3m / Revenue TTM 455.9m)
Gross Margin = 83.96% ((Revenue TTM 455.9m - Cost of Revenue TTM 73.1m) / Revenue TTM)
Gross Margin QoQ = 83.88% (prev 84.39%)
Tobins Q-Ratio = 4.51 (Enterprise Value 3.76b / Total Assets 834.3m)
Interest Expense / Debt = 6.29% (Interest Expense 1.35m / Debt 21.4m)
Taxrate = 16.88% (4.10m / 24.3m)
NOPAT = 55.4m (EBIT 66.7m * (1 - 16.88%))
Current Ratio = 2.11 (Total Current Assets 668.4m / Total Current Liabilities 316.9m)
Debt / Equity = 0.05 (Debt 21.4m / totalStockholderEquity, last quarter 447.7m)
Debt / EBITDA = -3.36 (Net Debt -259.9m / EBITDA 77.4m)
Debt / FCF = -1.87 (Net Debt -259.9m / FCF TTM 139.1m)
Total Stockholder Equity = 388.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.15% (Net Income 76.3m / Total Assets 834.3m)
RoE = 19.63% (Net Income TTM 76.3m / Total Stockholder Equity 388.9m)
RoCE = 16.25% (EBIT 66.7m / Capital Employed (Equity 388.9m + L.T.Debt 21.4m))
RoIC = 14.26% (NOPAT 55.4m / Invested Capital 388.9m)
WACC = 8.64% (E(4.26b)/V(4.28b) * Re(8.66%) + D(21.4m)/V(4.28b) * Rd(6.29%) * (1-Tc(0.17)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.33%
[DCF Debug] Terminal Value 79.46% ; FCFE base≈123.0m ; Y1≈151.7m ; Y5≈258.9m
Fair Price DCF = 16.01 (DCF Value 3.91b / Shares Outstanding 244.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.48 | EPS CAGR: 50.80% | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.63 | Revenue CAGR: 17.93% | SUE: 1.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=-0.005 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.025 | Revisions Net=+7 | Growth EPS=+7.4% | Growth Revenue=+16.9%
Additional Sources for CLBT Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle